Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial-Reference-Cited by-同舟云学术

Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial

Published:2022-12 Issue: Volume:177 Page:63-71
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Apolo Andrea B.^ORCID,Powles Thomas,Escudier Bernard,Burotto Mauricio,Zhang Joshua,Simsek Burcin^ORCID,Scheffold Christian,Motzer Robert J.,Choueiri Toni K.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

2. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma;Motzer;Cancer,2022

3. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma;Choueiri;N Engl J Med,2021

4. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial;Motzer;Lancet Oncol,2022

5. US highlights of prescribing information,2022

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors;Journal of Clinical Oncology;2024-09-01

2. Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic;Research and Reports in Urology;2024-07

3. Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage;Pharmaceutics;2024-05-29

4. Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma;Biomedicines;2024-05-16

5. First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy;BJU International;2024-04-24